Dataset Information


Biosimilar Pegfilgrastim: Improving Access and Optimising Practice to Supportive Care that Enables Cure.

ABSTRACT: Febrile neutropenia (FN) is a serious complication of chemotherapy, which can cause significant morbidity and mortality, result in dose delays and reductions and, ultimately, reduce cancer survival. Over the past decade, the availability of biosimilar filgrastim (short-acting granulocyte colony-stimulating factor [G-CSF]) has transformed patient access, with clear evidence of clinical benefit at preventing FN at reduced costs. In 2019, seven biosimilar pegfilgrastims (long-acting G-CSFs) were licensed, creating optimal market conditions and choice for prescribers. FN affects up to 117 per 1000 cancer patients, with mortality rates in the range of 2-21%. By reducing FN incidence and improving chemotherapy relative dose intensity (RDI), G-CSF has been associated with a 3.2% absolute survival benefit. Guidelines recommend primary prophylaxis and that filgrastim be administered for 10-14 days, while pegfilgrastim is administered once per cycle. When taken according to the guidelines, pegfilgrastim and filgrastim are equally effective. However, in routine clinical practice, filgrastim is often under-dosed (


PROVIDER: S-EPMC7211191 | BioStudies | 2020-01-01

REPOSITORIES: biostudies

Similar Datasets

2015-01-01 | S-EPMC4584106 | BioStudies
2018-01-01 | S-EPMC6127997 | BioStudies
2019-01-01 | S-EPMC6814815 | BioStudies
1000-01-01 | S-EPMC5380704 | BioStudies
2017-01-01 | S-EPMC5357483 | BioStudies
1000-01-01 | S-EPMC3559272 | BioStudies
2020-01-01 | S-EPMC7378111 | BioStudies
2018-01-01 | S-EPMC6199230 | BioStudies
2016-01-01 | S-EPMC4752449 | BioStudies
1000-01-01 | S-EPMC6240200 | BioStudies